Epirubicin vs Combination Chemotherapy for Pancreatic Cancer
Author Information
Author(s): C. Topham, J. Glees, N.S.B. Rawson, E.M. Woods, R.C. Coombes
Primary Institution: St Luke's Hospital, Guildford, UK
Hypothesis
Does combination chemotherapy provide better survival outcomes than single-agent epirubicin in patients with locally advanced and metastatic pancreatic cancer?
Conclusion
Combination chemotherapy does not provide a survival benefit over single-agent epirubicin for pancreatic cancer treatment.
Supporting Evidence
- Survival rates were not significantly different between the two treatment groups.
- The 1-year survival rate was 23.2% for the combination group and 15.4% for the epirubicin group.
- Patients without metastases had a significantly higher 6-month survival rate than those with metastases.
Takeaway
This study found that using just one drug, epirubicin, is just as good as using a mix of drugs for treating pancreatic cancer.
Methodology
Patients were randomized to receive either combination chemotherapy (5-fluorouracil, epirubicin, and mitomycin C) or epirubicin alone, with survival and response to treatment assessed.
Potential Biases
Potential bias due to the small number of patients and the fact that some patients refused treatment after randomization.
Limitations
The study had a small sample size and a wide confidence interval for survival rates.
Participant Demographics
Patients with locally advanced and metastatic pancreatic cancer, unselected for prior treatment.
Statistical Information
P-Value
0.55
Confidence Interval
95% CI 8.6-42.7% for FEM, 95% CI 5.1-31.7% for epirubicin
Statistical Significance
p=0.55
Want to read the original?
Access the complete publication on the publisher's website